Avai Bio

AVAI · OTC

$0.115+$0.003 (+2.68%)TodayMarket closed ·
Prev close $0.112

Latest news

  • Press releaseGlobe Newswire

    Avaí Bio and Austrianova Successfully Encapsulate GMP-Quality Klotho-Producing Cells, Achieve Robust Klotho Secretion

  • Press releaseGlobe Newswire

    Avaí Bio and Austrianova Complete Adventitious Agent Testing of Master Cell Bank, Establish Working Cell Bank for α-Klotho Anti-Aging Therapy

  • Press releaseGlobe Newswire

    Replacing Insulin Cells Works. Keeping The Cells Alive Is the Trick

  • Press releasePRNewswire

    A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up

  • Press releasePRNewswire

    Avaí Bio and Austrianova Reach Agreement for Insulin-Producing Cells with Internationally Acclaimed Partner to Advance Diabetes Therapy

  • Press releasePRNewswire

    The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy

  • Press releasePRNewswire

    Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum

  • Press releasePRNewswire

    Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets

  • Press releasePRNewswire

    Avaí Bio and Austrianova Complete GMP Master Cell Bank, Begin Viral Testing for Cell-Based Klotho Anti-Aging Therapy

  • Press releasePRNewswire

    A Unique Klotho-based Anti-Aging Therapy to Be Introduced at a Premier Longevity Forum: Inside Avaí Bio's Cell-Based Platform Approach

  • Press releaseGlobe Newswire

    Five Under-the-Radar Stocks With Catalysts Already in Motion — Across AI Defense, Space, Longevity, Gold, and Post-Quantum Security

  • Press releaseGlobe Newswire

    The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial

  • Press releasePRNewswire

    Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells

  • Press releaseGlobe Newswire

    The Credibility Filter Wall Street Uses to Sort Biotech Winners

  • Press releasePRNewswire

    Avaí Bio and Austrianova to Present Latest Data on Klotho Anti-Aging Therapy at Annual Klotho Conference

  • Press releasePRNewswire

    Why Smart Money Is Shifting From Clinical Data to Manufacturing Lines

  • Press releasePRNewswire

    The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step

  • Press releasePRNewswire

    Scalable Biotech Manufacturing Unlocks a $14B Market

  • Press releasePRNewswire

    Anti-Aging Protein Research Takes a Step Forward with Cell Cloning

  • Press releasePRNewswire

    Advanced Cell-based Therapy Booming the Success for Healthcare Sector

  • Press releaseGlobe Newswire

    The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven't Noticed

  • Press releasePRNewswire

    A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It.

  • Press releasePRNewswire

    Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them

  • Press releasePRNewswire

    Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone

  • Press releasePRNewswire

    Avaí Bio and Austrianova Begin Production of Master Cell Bank for Klotho Anti-Aging Therapy Under GMP Standards

  • Press releaseGlobe Newswire

    5 Stocks Sitting on the Right Side of the Biggest Repricing in a Generation

  • Press releasePRNewswire

    Avant Technologies Completes Rebranding with Name Change to Avaí Bio and Launch of New Website

  • Press releasePRNewswire

    AI in Healthcare Just Crossed a Tipping Point. Investors Are Watching These Names

  • Press releaseGlobe Newswire

    Global Artificial Intelligence Influence on Diabetic Retinopathy Market Expected to See Significant Growth

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.